Reason for request
Reassessment
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of KYMRIAH 1.2 x 106 – 6 x 108 cells (tisagenlecleucel) dispersion for infusion is substantial in the treatment of paediatric and young adult patients up to and including 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse.
|
Clinical Added Value
| moderate |
Considering:
- the updated efficacy data from the ELIANA clinical study, confirming the results previously analysed, particularly in terms of complete remission percentage, with this remission remaining durable in some patients (approximately 1/3 to 1/2), following a median follow-up of 79.1 months between injection of KYMRIAH (tisagenlecleucel) and the database freeze for this last analysis in the ELIANA study,
- the overall survival results, with a median of 47.9 months (CI95% [19.4; NE]) in the 97 patients included (ITT population) in ELIANA, in clinical situations that are life-threatening in the short term and for which the available treatment options do not enable a complete recovery to be envisaged,
- the safety profile marked by significant short-term toxicity,
- additional experience with respect to the real-world data in the DESCAR-T registry (median follow-up duration since eligibility of 19.4 months, 19 activated centres, 99 patients treated with KYMRIAH (tisagenlecleucel)), suggesting results consistent with those of the clinical studies,
- despite the initial uncertainties identified, which persist, particularly with respect to:
- the exact effect size compared to therapeutic management, in the absence of any robust comparison,
- the qualitative weakness of the data in the DESCAR-T registry (data not monitored),
- maintenance of the clinical efficacy in the long term, particularly concerning achievement of full recovery for patients in lasting remission,
- and the absence of long-term safety data,
The Committee considers that its previous conclusions are not liable to be modified. On the basis of currently available data, KYMRIAH 1.2 x 106 – 6 x 108 cells (tisagenlecleucel) dispersion for infusion still provides a moderate clinical added value (CAV III) in the care pathway for the treatment of paediatric and young adult patients with B-cell ALL that is refractory, in relapse post-transplant or in second or later relapse.
|
eNrNWF1v2jAUfedXRHk3KaWfU6DaWLshrRqjRZv2Ut0kN8TU2Kk/KOzXzyF0o1WitqGW+oLANufe+B6fe+LwbDln3gKlooL3/E57z/eQxyKhfNrzJ9cX5MQ/67fCGSzAixko1fOL7+0Igav2r8tvn9GuRun3W14oohnG+tE6oylrfwWVXUJerPHChaCJN0ediaTn50avR71QaWlj9u+FvFU5xBgGm5Ht2dnNwfZ4GBRgL0A1CuU34NNKUOSNMGMjJXI9AI1TIVc1+XYbYVM1RiWMjHEEOhtJsaAJJpUhUmAKGwVJ75MrlAuGughSCR7M4rlqBA4zWI7xblid9Ec7O9BLTfZI5/j0cL+73z3pnh7tNQolt7aqugr2IYL8pntwdGxDBciD29VcUsiIpgqmyBnGDE2MjETEfjICsdFI2GqeZyKybNY0JnbFLeCcAgG7QmegCVVEYioh1k8I8IpCj4TUwByVmKrBY5Y6iiPx7lkqJVTlDFbtmcqbbhVIsNMorZa4e5DiCa6lVTdm9+wJPjeMBa/MerLRHkcZF9I2EIbrGgm6GDfdiIHgGpf1FW2mmnq54SJF9XawfwSv7hgjEzEaN9VHq2AGlZ6Mh/Xy+G6V5RMonEh30vKT8kTcq7eXrG2KOMo+X6tuJWguk87N/unJUefwsPGJ/G35WNP7zo0UOQZWzKjaRaOGPBW7qpOleDXUA8HfJ7fXdk7EwLDG0JGGqmdJ/eA/nR0bd0eynKgE/XJ+3ZRrPwzK1dX6ZyU0TXr/WNKsJbjoM5bZtYm//pyUcuHE6htZLUOZ1rn6EAQZKKLA7lA7le+732z5BXdvLE5MSWnSSs12lHpUNuOXl7rpcX3Osuxqwzf/39j9yhhaGtyhDqWyO9Pf4fnbS/p/D+4s7dEjCXIXZu2XQVPBXVkvE1X7rp2aiK0rv5BWHL6nKa25ParlZRiUN1f9VhgUt1b91l/jo1ON
U9WEAmsW9etT0JQa